Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

Mocetinostat (MGCD0103) is an orally administered HDAC inhibitor. Durvalumab (MEDI4736) is a human monoclonal antibody that is an inhibitor of the Programmed Cell Death Ligand (or PD-L1). Durvalumab is also known as a checkpoint inhibitor. This study is evaluating the combination regimen of mocetinostat and durvalumab in participants with Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02805660.

Trial PhasePhase I/II

Trial Typetreatment

Lead OrganizationMirati Therapeutics

• Primary ID0103-020
• Secondary IDsNCI-2016-01189
• ClinicalTrials.gov IDNCT02805660